LONDON, UK / ACCESSWIRE / October 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Inovio Pharmaceuticals, Inc. (NASDAQ: INO), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=INO. The Plymouth Meeting , Pennsylvania based clinical-stage pharmaceutical Company announced on October 16, 2017, that it has commenced a phase-1b/2 immuno-oncology trial to evaluate Genentech/Roche's atezolizumab (TECENTRIQ®) in combination with Inovio's INO-5401and INO-9012 for the treatment of advanced bladder cancer. For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on INO. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=INO

Combining INO-5401/INO-9012 with atezolizumab may provide a synergistic therapeutic effect as a result of generating higher levels of activated T cells and simultaneously inhibiting PD-L1.

About INO-5401

Inovio's INO-5401, an immunotherapy encoding multiple cancer antigens (HTERT, PSMA, and WT1), is designed to generate and activate T cells to many cancer types including bladder cancer. INO-9012, a DNA-based immune activator encoding IL-12, is designed to amplify and accelerate T cell immune responses to INO-5401.

Phase- 1b/2 Immuno-Oncology Trial

The multi-center, open-label efficacy trial to evaluate the safety, immune response and clinical efficacy of the combination therapy will be managed by Inovio, and Genentech will supply atezolizumab. Around 80 patients with advanced bladder cancer, specifically advanced unresectable or metastatic urothelial carcinoma (UC), will be enrolled. Most of the enrolled patients will have previously received and failed to demonstrate a meaningful response to an anti-PD-1 or PD-L1 checkpoint inhibitor alone.

The study, therefore, will evaluate the potential benefit of a checkpoint inhibitor combined with a DNA-based immunotherapeutic and T cell activator within a bladder cancer patient population with very limited treatment options and poor outcomes. The immunologic analysis accompanying the study will provide further insight into mechanisms of checkpoint inhibition and T cell activation in bladder cancer.

Inovio Can Demonstrate Immense Potential of INO-5401 as a Universal Cancer Immunotherapy

Dr. J. Joseph Kim, President and CEO of Inovio, stated that combining INO-5401 with TECENTRIQ may provide a synergistic therapeutic effect as a result of generating high levels of activated T cells and simultaneously inhibiting PD-L1. The Company's approach is to augment the anti-PD-1/PD-L1 driven efficacy by further enhancing the T cells against the tumor in a cancer antigen-specific manner. J. Joseph added that Inovio believes it can demonstrate the immense potential of INO-5401 as a universal cancer immunotherapy to treat patients with multiple cancers.

FDA Granted Approval to Various Drugs for Treating UC

In 2017, the US Food and Drug Administration (FDA) granted regular and accelerated approvals to various drugs for the treatment of UC based on the clinical trials, including Bristol-Myers Squibb's Nivolumab, Merck and Co.'s Pembrolizumab, BAVENCIO, EMD Serono, Inc.'s Avelumab, and AstraZeneca UK Limited's IMFINZI.

What is TECENTRIQ (Atezolizumab)?

TECENTRIQ is a cancer immunotherapy which is a medicine designed to work with the body's own immune system. TECENTRIQ is the first and only approved anti-PDL1 medicine for people with specific types of advanced urothelial carcinoma, including bladder cancer and non-small cell lung cancer, and it is a registered trademark of Genentech.

What is Metastatic Urothelial Carcinoma (UC)?

Metastatic Urothelial Carcinoma is the most common type of bladder cancer. The prognosis for patients with advanced unresectable or metastatic UC is poor with limited treatment options. It is a disease that has seen no major advances for more than 30 years. Expected survival is generally less than 12 months.

About Inovio Pharmaceuticals, Inc. and Genentech

Founded in 1983, Inovio Pharma is a clinical-stage pharma revolutionizing the fight against cancer and infectious diseases.

Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. In 2009, Roche and Genentech combined their pharmaceutical operations in the United States.

Last Close Stock Review

On Tuesday, October 17, 2017, the stock closed the trading session at $6.24, slightly rising 0.48% from its previous closing price of $6.21. A total volume of 507.78 thousand shares have exchanged hands. Inovio Pharma's stock price advanced 4.00% in the last one month and 2.30% in the past six months. The stock currently has a market cap of $571.08 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily